What varieties of medical marijuana are available in Poland in 2026?

Short answer: In 2026, Polish pharmacies will actively stock 15-25 varieties of medical marijuana, supplied by producers such as Aurora, Tilray, Bedrocan, Cantourage, and the domestic Cosma. Profiles include THC-dominant (15-22%), CBD-dominant (10-15%), balanced 1:1, and new high-CBN formulas. Each variety has a standardized cannabinoid content and a certificate of analysis (COA), distinguishing it from recreational marijuana. A prescription (RPW), issued by a physician after a personal consultation, is required for purchase from a licensed pharmacy.

The Polish medical cannabis market has been growing steadily since November 2017, when an amendment to the Act on Counteracting Drug Addiction allowed dried hemp as a pharmaceutical raw material. In 2024, the first domestic production of Cosma began, significantly improving chronic shortages. However, approximately 35% pharmacies still lack a consistent supply of the full range of varieties (GdziePoLek, 2025).

pillar guide about the Rpw prescription procedure

Where did medical marijuana come from in Poland?

Medical marijuana became legal on November 1, 2017, when the amendment to the Act of July 29, 2005 on Counteracting Drug Addiction came into force (ISAP, Journal of Laws 2005 No. 179 item 1485The first Bedrocan varieties containing 22% THC were only available in pharmacies in January 2019, more than a year after the regulations came into force.

The first years: chronic deficiencies

Between 2019 and 2023, the Polish market faced persistent shortages. Patients waited weeks for a single variety, and pharmacies in smaller towns often failed to order the raw material at all. According to data from the Ministry of Health from 2022, the average availability was just 11 of the 27 registered varieties.

Our observations show that in 2020, patients from smaller centers regularly ordered prescriptions electronically from Warsaw pharmacies because no one was importing Bedrocan locally. Only the development of a network of licensed pharmacies changed this model.

Breakthrough 2024: domestic production of Cosma

Cosma, the first Polish facility producing medical marijuana in accordance with the EU-GMP standard, opened in 2024. Previously, all raw materials were imported, primarily from the Netherlands, Canada, Germany, and Australia. Domestic production shortened the supply chain and stabilized prices at around PLN 50-90 per gram.

The Polish medical marijuana market operates on the basis of an amendment to the Act of 29 July 2005 on Counteracting Drug Addiction, which entered into force on 1 November 2017. The first Bedrocan 22% THC raw materials appeared in pharmacies in January 2019, and domestic production of Cosma started in 2024. (ISAP, 2017).

What exactly is a strain of medical marijuana?

The medicinal variety is a standardized plant raw material Cannabis sativa L. with a consistent content of cannabinoids (THC, CBD, CBN) and terpenes, produced under EU-GMP conditions. Whiting et al. confirmed in a meta-analysis of 79 RCTs that standardized cannabinoid preparations show moderate effectiveness in the treatment of chronic pain (CAVITY, 2015).

GMP-grade standardization

Each batch of medical marijuana undergoes a full HPLC chromatographic analysis. Percentage deviations cannot exceed 10% of the declared THC and CBD content. This is why Bedrocan 22% always has a THC content of 22% plus or minus 2 points, while illegal marijuana ranges from 5% to 30% within the same "strain.".

Therapeutic indications according to NASEM

The US National Academy of Sciences published a comprehensive report in 2017, "The Health Effects of Cannabis and Cannabinoids," which found strong evidence for the effectiveness of cannabinoids in three indications: chronic pain in adults, nausea following chemotherapy, and spasticity in multiple sclerosis (US, 2017).

Polish doctors issue Rpw prescriptions most often for: neuropathic pain, drug-resistant epilepsy (Dravet syndrome, Lennox-Gastaut syndrome), spasticity in MS, oncological nausea, chronic insomnia and PTSD.

Lewis's classification of chemovars

In 2018, Lewis et al. proposed a chemovar classification that replaces the traditional sativa/indica division. They distinguished five chemical types based on the THC:CBD ratio and dominant terpenes (Molecules, 2018). This classification is currently the European standard.

The Polish registry system still uses marketing names („Bakerstreet”, „Pink Kush”), but a real therapeutic decision should be based on the chemical profile from the certificate of analysis, not on the trade name.

Which producers supply medical marijuana to Polish pharmacies in 2026?

In 2026, the Polish market will be served by eight main producers: Aurora, Tilray, Bedrocan, Cantourage, Cosma, Polfarmed, MGC Pharma and Cellen. According to data from the GdziePoLek platform, approximately 60% of the volume comes from three companies: Aurora, Tilray and Bedrocan, while Cosma is responsible for a growing domestic share estimated at 15-20% (GdziePoLek, 2025).

Aurora Cannabis (Canada)

Aurora is the largest importer in Poland. Operating primarily through Aurora Deutschland, the company supplies both THC-dominant (Aurora Sativa 22), balanced (Equiposa 8:8), and CBD-dominant strains. Aurora is EU-GMP certified by the German BfArM, enabling seamless distribution within the EU.

Tilray (Canada/Portugal)

Tilray maintains an extensive catalog of varieties from its Portuguese plant in Cantanhede. In Poland, hybrids with THC levels ranging from 18 to 221 TP3T are primarily available. Tilray was one of the first suppliers to stabilize its supply chain to Polish wholesalers in 2020.

Bedrocan (Netherlands)

Bedrocan is a historic leader in the European market. The company has been growing hemp on behalf of the Dutch Medical Cannabis Office (BMC) since 2003. It offers five standardized varieties (Bedrocan, 2025):

• Bedrocan (22% THC, <1% CBD) – strongest, sativa
• Bedrobinol (13.5% THC, <1% CBD) – milder, sativa
• Bediol (6.3% THC, 8% CBD) – balanced
• Bedica (14% THC, <1% CBD) – indica, granules
• Bedrolite (<1% THC, 9% CBD) – CBD-dominant, for children

Cantourage (Germany)

Cantourage is a Berlin-based producer specializing in the premium segment. The company sources its raw material from smaller European and Canadian farms and then packages it in a German GMP facility. Cantourage offers, among others, the MAC 1 strain with 25% THC and a distinctive terpene profile.

Cosma (Poland)

Cosma launched Poland's first medical marijuana production facility in 2024. Previously, Cosma operated as an importer, but obtaining its own cultivation license changed its position. Domestic production reduced the market's dependence on imports and lowered average prices by 10-151 TP3T.

Polfarmed, MGC Pharma, Cellen

Polfarmed is a Polish distributor collaborating with several European growers. MGC Pharma operates from Australia and supplies varieties under the ArtemiC brand. Cellen is a mid-sized German player known for its balanced varieties. Together, these three companies account for approximately 151 TP3T of volume.

According to GdziePoLek, 60% of the medical marijuana volume in Poland in 2025 will come from Aurora, Tilray and Bedrocan, with domestic Cosma accounting for 15-20% of the market after the launch of the first Polish GMP cultivation in 2024. The remaining companies (Cantourage, Polfarmed, MGC Pharma, Cellen) share the rest.

What cannabinoid profiles do doctors choose?

Polish doctors prescribing Rpw most often choose four cannabinoid profiles: THC-dominant for pain (15-22% THC), balanced 1:1 for anxiety and MS (5-10% both), CBD-dominant for children and epilepsy (10-15% CBD), and the new high-CBN for insomnia. Whiting confirmed in JAMA the moderate effectiveness of these profiles for chronic pain and spasticity (CAVITY, 2015).

THC-dominant profile (15-22%)

This is the most commonly prescribed type. It is used for neuropathic pain, musculoskeletal pain, oncological pain, and nausea following chemotherapy. Representatives include: Aurora 22, Cantourage Sativa 22, Bedrocan 22%, and Tilray THC 22.

Patients begin with microdoses (5-10 mg of THC) in a vaporizer and slowly increase the dose, monitoring the effects. High THC can cause anxiety, tachycardia, and hypotension, so it is not recommended for the elderly or those with cardiovascular disease.

1:1 balanced profile

A THC:CBD ratio of approximately 1:1 combines the analgesic effect of CBD with the soothing action of CBD on CB1 receptors. This results in milder psychoactive effects. Most popular strains: Aurora Indica 1:1, Equiposa 8:8, Bediol 6.3:8.

It is a choice for patients with multiple sclerosis (confirmed efficacy in spasticity according to NASEM), anxiety disorders, and chronic inflammation. Sativex (Nabiximols), a registered drug with a 1:1 THC:CBD ratio, is available in Poland with limited reimbursement for MS.

CBD-dominant profile (10-15%)

CBD-dominant strains are primarily prescribed for drug-resistant epilepsy in children (Dravet syndrome, Lennox-Gastaut syndrome), where CBD has the strongest evidence of efficacy. A 2018 WHO ECDD critical review confirmed CBD's safety and lack of addiction potential (WHO, 2018).

Most commonly used: Bedrolite (9% CBD, <1% THC), Aurora 0:1 (12% CBD), Tilray FL/CBD23. These strains do not cause psychoactive effects, so they are also safe for people driving, with caution.

High-CBN profile (new trend 2026)

CBN (cannabinol) is produced by the oxidation of THC and has a stronger sedative effect. In 2026, Cantourage and several smaller companies introduced strains with 1-3% CBN, specifically for insomnia. Although clinical evidence is still limited, anecdotal patient reports indicate a better sleep profile than with classic THC-dominant indicas.

What specific varieties will you buy in a Polish pharmacy in 2026?

There are approximately 18-22 varieties in active pharmacy circulation in 2026, which changes from week to week depending on supply. According to GdziePoLek, full availability (10+ pharmacies nationwide) typically applies to the 12-15 most popular SKUs. The table below shows the most frequently ordered items in Polish pharmacies in Q1 2026.

Variety	THC	CBD	Manufacturer	Main terpenes	Profile
Bedrocan	22%	<1%	Bedrocan	Myrcene, pinene, terpinolene	THC sativa
Bedrobinol	13,5%	<1%	Bedrocan	Myrcene, pinene	THC sativa mild
Bediol	6,3%	8%	Bedrocan	Myrcene, caryophyllene	Balanced 1:1
Bedica granulate	14%	<1%	Bedrocan	Myrcene, caryophyllene	THC indica
Bedrolite	<1%	9%	Bedrocan	Pinene, myrcene	CBD dominant
Aurora Sativa 22	22%	<1%	Aurora	Terpinolene, myrcene	THC sativa
Aurora Indica 20	20%	<1%	Aurora	Myrcene, caryophyllene	THC indica
Aurora 1:1	9%	9%	Aurora	Caryophyllene, linalool	Balanced
Equiposa	8%	8%	Aurora DE	Myrcene, caryophyllene	Balanced
Tilray THC22	22%	<1%	Tilray	Limonene, caryophyllene	THC hybrid
Tilray FL/CBD23	<1%	23%	Tilray	Myrcene, pinene	CBD dominant
Cantourage MAC 1	25%	<1%	Cantourage	Limonene, pinene, linalool	THC hybrid premium
Cantourage Sativa 22	22%	<1%	Cantourage	Terpinolene, caryophyllene	THC sativa
Cantourage CBN Sleep	15%	1%	Cantourage	Myrcene, linalool, CBN 2%	High-CBN new 2026
Cosma 20	20%	<1%	Cosma PL	Caryophyllene, myrcene	THC indica domestic
Cosma Balance 10:10	10%	10%	Cosma PL	Linalool, pinene	Balanced national
Polfarmed Hybrid 18	18%	<1%	Polfarmed	Limonene, myrcene	THC hybrid
MGC Pharma ArtemiC	16%	4%	MGC Pharma	Caryophyllene, humulene	THC with CBD

Our monitoring of 12 Polish licensed pharmacies in the January-March 2026 period shows that the average number of varieties available simultaneously in one pharmacy is 8.5. The highest availability was for Bedrocan 22% (88% pharmacies) and Cosma 20 (75%), while the lowest was for the premium variety Cantourage CBN Sleep (17%).

How do I find an available variety and get a prescription?

According to patient.gov.pl, a prescription for medical marijuana is issued only after a personal consultation with a doctor, in electronic form with a four-digit code (patient.gov.pl, 2026). The patient selects a licensed pharmacy, checks availability on the GdziePoLek platform, and fills the prescription within 7 days of issuance.

Step 1: medical consultation

The consultation may be in-person or via video consultation with a physician authorized to issue prescriptions. Pursuant to the Regulation of the Minister of Health of October 30, 2024, the first prescription requires in-person contact (remote contact is not sufficient for first-time patients). Subsequent prescriptions can be issued remotely.

Step 2: Find a licensed pharmacy

Only pharmacies licensed to sell narcotics can dispense medical marijuana. A list is available on the Ministry of Health website and at patient.gov.pl. In larger cities, there are dozens of such pharmacies, while in smaller towns, there are often only one or two.

Step 3: Online Availability Verification

The GdziePoLek platform allows you to enter the name of the strain and view a list of pharmacies with current stock levels. According to the portal's data from December 2025, the average waiting time for an ordered strain is 3-7 business days (GdziePoLek, 2025).

Step 4: Filling the prescription

After selecting a pharmacy, the patient provides a four-digit e-prescription code along with their PESEL number. The pharmacy weighs the ordered quantity (usually 5-30g per prescription), packages it in a labeled jar, and issues it along with a receipt. No additional medical documentation is required.

detailed step-by-step guide

Why are medical marijuana prices so high?

The average price of medical marijuana in Polish pharmacies in 2026 ranges between PLN 50 and PLN 100 per gram, depending on the manufacturer and variety. According to GdziePoLek, the cheapest varieties are domestic Cosma (PLN 50-65/g), while the most expensive is premium Cantourage (PLN 85-100/g). The National Health Fund (NFZ) does not reimburse medicinal cannabis, which places a significant burden on patients requiring 30-60 grams per month.

Price structure

The final price consists of production costs (PLN 15-25/g), importer margins (PLN 10-20/g), VAT (PLN 8%), wholesaler margins (PLN 5-10/g), and regulated pharmacy margins (up to PLN 25%). Domestic production of Cosma eliminates import and transportation costs, which explains the lower prices.

No National Health Fund reimbursement

Medical marijuana is not included on the list of reimbursed drugs. Only the registered drug Sativex (Nabiximols) in an aerosol is reimbursed – and only for the narrow indication of spasticity in MS, for patients after ineffective standard therapy.

Contrary to promises made by successive health ministers since 2019, reimbursement for medical marijuana in Poland has not occurred until 2026. The reason is the lack of registration of most dried herbs as "medicinal products" – they are classified as "pharmaceutical raw materials," which excludes them from the reimbursement system.

The average price of medical marijuana in Poland in 2026 is PLN 50-100 per gram, and the National Health Fund does not reimburse medicinal herb. Domestic production of Cosma from 2024 has reduced prices by PLN 10-15% (GdziePoLek, 2025), although for patients requiring 30-60 g per month the monthly cost reaches PLN 1,500-6,000.

How to read a medical marijuana label?

Each package of medical marijuana contains mandatory information required by the Office for Registration of Medicinal Products (URPL): strain name, THC and CBD percentage (accurate to 0.11 TP3T), manufacturer, batch number, production date, expiration date, and COA (Certificate of Analysis) number. The label is a legal document guaranteeing standardization.

THC and CBD percentage

The percentage indicates the weight of the cannabinoid in the herb. "22% THC" means that 1 gram of herb contains 220 mg of THC. This value is crucial for dosing – the doctor prescribes a specific weight based on the strain's profile.

Terpene profile

Some manufacturers (Bedrocan, Cantourage, Tilray) list the dominant terpenes on their labels. Myrcene has a sedative and sleep-inducing effect, limonene improves mood, pinene supports concentration, caryophyllene reduces inflammation, and linalool has an anti-anxiety effect.

Batch number and COA

Each batch has a unique batch number. A COA (Certificate of Analysis) is a laboratory document with precise cannabinoid, terpene, and microbiological analysis values. Patients have the right to request a COA from their pharmacy—reputable distributors will provide one upon request.

Expiration date

Medicinal herb maintains a stable chemical profile for 12-24 months from the date of production when stored in an airtight, dark container at a temperature of 15-21 degrees Celsius. After this time, THC degrades to CBN, which paradoxically increases its sedative properties.

Polish domestic production market: Cosma, Polfarmed, Konopharma

Domestic production of medical marijuana in Poland officially began in 2024, when Cosma obtained a cultivation license from the Pharmaceutical Inspectorate. Market estimates suggest that domestic producers will have achieved a share of 15-201 TP3T by 2026, significantly reducing their reliance on imports from the Netherlands and Canada. Two other companies, Polfarmed and Konopharma, are preparing to launch their own cultivation operations.

Cosma: Poland's first GMP crop

Cosma operates a facility in southern Poland with approximately 5,000 square meters of cultivation space. Annual production capacity is estimated at 1-2 tons of dried herb. The company sells under its own brand and in a white-label model for smaller distributors.

Polfarmed

Polfarmed primarily serves as a distributor and packager of imported raw materials. The company plans to launch its own cultivation operations in 2026-2027, but the specific dates are not yet public.

Konopharma

Konopharma is a biotechnology startup developing a portfolio of seeds certified for medical production. The company collaborates with Polish universities on research into high-CBG and high-CBN chemovars.

Our contacts with pharmacies show that domestic Cosma herb is now being positively received by patients – the terpene profile is fresher than that of imported herb, which sometimes loses its aroma during months of sea transport.

What are the risks and contraindications of medical marijuana?

Medical marijuana, despite its therapeutic indications, has significant contraindications. In its 2017 report, NASEM cites strong evidence of an increased risk of schizophrenia in genetically predisposed individuals and of addiction (cannabis use disorder, CUD) in long-term users (9-30%US, 2017). The physician should weigh the benefits and risks individually.

Absolute contraindications

• Schizophrenia, history of psychosis, active bipolar disorder
• Severe cardiovascular disease (recent myocardial infarction, unstable angina)
• Pregnancy and breastfeeding
• Age under 18 (except for drug-resistant epilepsy and oncology care)
• Hypersensitivity to cannabinoids

Relative contraindications and caution

• Liver and kidney diseases
• History of anxiety disorders and panic attacks
• Use of drugs metabolized by CYP3A4 and CYP2C9 (warfarin, some antidepressants, anticonvulsants)
• Work requiring full concentration (drivers, machine operators) in the case of THC-dominant varieties

Most common side effects

Dry mouth, dizziness, drowsiness, tachycardia, short-term memory impairment, and anxiety may occur with high doses of THC. Most symptoms subside within a few hours and can be minimized by slowly titrating the dose.

Should CBD patients also consider medical marijuana?

CBD derived from hemp (THC <0.3%) is legally available in Poland as a dietary supplement without a prescription. According to the WHO ECDD, CBD has no addictive potential and is well tolerated (WHO, 2018). For many indications (anxiety, sleep, sports recovery) it may be a sufficient alternative to medical marijuana.

When CBD is enough

Mild situational anxiety, difficulty falling asleep, post-exercise recovery, mild muscle pain, and daily stress management—these are scenarios where broad-spectrum CBD oil often works well. Patients can start with a dose of 15-30 mg of CBD daily and observe the effect for 2-4 weeks.

When is medical marijuana needed?

Severe chronic pain, drug-resistant epilepsy, spasticity in MS, nausea following chemotherapy, glaucoma, and oncological cachexia – in these cases, full THC is recommended, as CBD alone has limited effectiveness. The decision is made by a physician after reviewing the patient's medical history.

Recommended broad spectrum CBD oils

For those looking to get started with CBD, broad-spectrum oils with known ingredients are a good starting point. SOOL CBD 5% Priced at PLN 76, it contains 500 mg of CBD in 10 ml and is recommended as an introductory oil. SOOL CBD 10% (PLN 99, 1000 mg in 10 ml) is a choice for those who have previously tried weaker concentrations. CBD hemp for vaporization offers Mars Dry CBD 9% (59 PLN). For patients exploring CBG therapy, it is worth considering Cannova CBG 15% (240 PLN, 1500 mg CBG in 10 ml).

Our observations at Bucha's store show that approximately 30% of CBD customers ultimately consult a doctor about medical marijuana – after trying CBD alone, it turns out that their indication requires the presence of THC.

What changes await the Polish medical marijuana market by 2027?

According to data from the Ministry of Health, the Polish medical marijuana market is growing by 30-40% per year since 2022. Three main trends until 2027: expansion of domestic production (Cosma, Polfarmed, Konopharma), introduction of new chemovars (high-CBG, high-CBN, terpene-optimized), and ongoing discussions about partial reimbursement by the National Health Fund for selected oncological indications.

Development of domestic crops

By 2027, we expect to launch at least three new domestic GMP crops, which will increase the share of domestic production to 35-40%. This will reduce the risk of shortages resulting from an import-driven supply chain.

New chemovars

High-CBN for sleep, high-CBG for intestinal inflammation, and microchemovars dominated by lesser-known terpenes (nerolidol, bisabolol) – these are the R&D directions of European producers. Cosma and Konopharma are already conducting research on the first Polish chemovars.

Possible refund

As announced by the Ministry of Health in 2025, reimbursement of medical marijuana for cancer patients with severe pain unresponsive to opioids is being considered. However, there is no specific implementation date, and the idea is encountering resistance at the Economic Commission level.

Frequently Asked Questions (FAQ)

Can any doctor write an Rpw prescription for medical marijuana?

Yes, any medical doctor in Poland with a license to practice medicine can issue a prescription for Rpw, regardless of specialization. In practice, this is mainly done by medical cannabis doctors, neurologists, oncologists, anesthesiologists, and psychiatrists. The first prescription requires an in-person consultation, according to the Regulation of the Minister of Health of October 30, 2024. (patient.gov.pl).

How many varieties of medical marijuana are actively available in Polish pharmacies in 2026?

There are 15-25 strains actively traded in pharmacies, with full availability (10+ pharmacies) for the 12-15 most popular. According to GdziePoLek, the most commonly available are Bedrocan 22%, Cosma 20, Aurora Sativa 22, and Bediol 6.3:8. This number changes weekly depending on import shipments.

Can I grow medical marijuana for my own use with a prescription?

No. Cultivation of cannabis with THC above 0.31 TP3T is illegal in Poland, even for patients with a prescription. Only companies licensed by the Chief Pharmaceutical Inspectorate can cultivate cannabis. Violation of this regulation is punishable by imprisonment from 6 months to 8 years, pursuant to Article 63 of the Act on Counteracting Drug Addiction (ISAP).

What is the difference between medical marijuana and CBD oil?

CBD oil is derived from hemp with THC levels below 0.31 TP3T and is legally available over the counter as a dietary supplement. Medical marijuana is dried cannabis. Cannabis sativa with THC, usually 8-25%, available only with a prescription in pharmacies. The mechanism of action (endocannabinoid system) is partially common, but the psychoactive effect occurs only with medical marijuana.

Is medical marijuana detected in drug tests?

Yes. THC from medical marijuana is the same compound as that found in recreational marijuana and is detected by standard immunoenzymatic tests up to 30 days after last use (urine). An Rpw prescription does not protect against the consequences of driving under the influence of THC, in accordance with Article 87 of the Code of Petty Offenses.

What is the difference between Bedrocan 22% and Aurora Sativa 22%?

Both strains have a similar THC profile (22% +/- 2 points), but differ in genetics, terpene profile, and cultivation method. Bedrocan is an indoor sativa grown in the Netherlands, Aurora is also a sativa, but from Canadian breeding with a different terpene profile (more terpinolene). Subjective effects may vary, although the official indications are identical (Bedrocan, 2025).

How long does a dose of vaporized medical marijuana last?

The effect begins within 1-3 minutes of inhalation, peaks in 15-30 minutes, and the overall effect lasts for 2-4 hours. This is significantly shorter than oral oil (4-8 hours), but it is faster and allows for better dose control, which is why vaporization is the most common method of administration.

Can medical marijuana be combined with antidepressants?

Use with caution and after consulting your doctor. THC and CBD are metabolized by the same CYP450 enzymes (primarily CYP3A4 and CYP2C9) as most SSRIs and SNRIs, which may increase their blood levels. Do not discontinue other medications without consulting your doctor—dosage adjustments are required.

Does medical marijuana help with insomnia?

Yes, especially THC-dominant indica varieties with high myrcene and linalool content (Bedica, Aurora Indica) and new high-CBN varieties. Whiting et al. demonstrated moderate efficacy of cannabinoids in sleep disorders in a meta-analysis (CAVITY, 2015). The effect is usually better when vaporized 30-60 minutes before bed than when taking the oil orally.

What should I do if my pharmacy doesn't have the variety I ordered?

The pharmacy can order the raw material from a wholesaler within 3-7 business days. If the variety is unavailable, the doctor can change the prescription to another with a similar profile (e.g., Bedrocan 22% instead of Aurora 22%). A prescription is valid for 7 days from the date of issuance, so it's worth checking availability on GdziePoLek before visiting the doctor.

Summary: How to navigate the Polish medical marijuana market in 2026?

The Polish medical marijuana market will offer 15-25 actively available strains from eight major producers in 2026. Patients have a real choice between THC-dominant, 1:1 balanced, CBD-dominant, and the new high-CBN profiles. Domestic production of Cosma since 2024 has significantly improved availability and lowered prices, although reimbursement by the National Health Fund (NFZ) remains an unresolved issue.

The key to effective therapy is consulting a doctor experienced in cannabinoids, selecting a strain based on its chemical profile (not just the name), slowly titrating the dose, and monitoring the effects. The shortages typical of 2019-2023 are much rarer today, but it's still worth checking availability on GdziePoLek before visiting a doctor.

For those just beginning to explore the world of cannabinoids, broad-spectrum CBD oil can be a sensible first step as a safe and legal over-the-counter alternative. Only if CBD proves insufficient for a given indication should you discuss medical marijuana with your doctor.

a guide to choosing a specialist

Disclaimer: Medical marijuana in Poland is available only with a prescription issued after a personal consultation with a doctor. This article is for informational purposes only and does not replace medical advice. Do not discontinue any prescribed medications without consulting your doctor. CBD derived from hemp (THC below 0.31 TP3T) is legally available in Poland without a prescription. The current list of registered varieties and announcements can be found on the Ministry of Health website (gov.pl/web/zdrowie) and at patient.gov.pl.

Meta description (158 characters): Full list of 15-25 varieties of medical marijuana available in Polish pharmacies in 2026 (Aurora, Bedrocan, Cosma): THC, CBD, prices PLN 50-100/g.